Abstract
Estrogen receptors (α and ß) are members of the steroid/thyroid nuclear receptors superfamily of ligand-dependent transcription factors. Impact of the ? isoform of estrogen receptor (ER) on breast cancer etiology and progression is now well established. Current therapeutic strategy to treat ER-positive breast cancer relies on the blockade of ER trancriptional activity by antiestrogens. Data accumulated during the last five years on the mechanism of action of ER enable one to foresee new strategies. These data indeed reveal that ER is not statically bound to DNA at promoter sites of genes regulating cell proliferation and/or differentiation, but rather behaves as a very mobile protein continuously shuttling between targets located within various cellular compartments (i.e. membrane, microsomes, nucleus...). This allows the receptor to generate both non-genomic and genomic responses. Ligands, growth factors and second messengers produced downstream of activated membrane receptors modulate ER-mediated responses by interfering with the traffic patterns of the receptor, as well as by locally blocking its transient anchorage. Changes in ER turnover rate associated with these regulatory processes seem also to strongly influence the ability of the receptor to mediate gene transactivation. The present paper surveys these biological data and analyzes how they may be integrated into new drug design programs aimed at expanding our therapeutic armamentarium against breast cancer.
Keywords: Estrogen receptor α, shuttling, trafficking, turnover, proteasome, breast cancer, transcription, signal transduction
Current Cancer Drug Targets
Title: Estrogen Receptor Alpha: Impact of Ligands on Intracellular Shuttling and Turnover Rate in Breast Cancer Cells
Volume: 6 Issue: 1
Author(s): Guy Leclercq, Marc Lacroix, Ioanna Laios and Guy Laurent
Affiliation:
Keywords: Estrogen receptor α, shuttling, trafficking, turnover, proteasome, breast cancer, transcription, signal transduction
Abstract: Estrogen receptors (α and ß) are members of the steroid/thyroid nuclear receptors superfamily of ligand-dependent transcription factors. Impact of the ? isoform of estrogen receptor (ER) on breast cancer etiology and progression is now well established. Current therapeutic strategy to treat ER-positive breast cancer relies on the blockade of ER trancriptional activity by antiestrogens. Data accumulated during the last five years on the mechanism of action of ER enable one to foresee new strategies. These data indeed reveal that ER is not statically bound to DNA at promoter sites of genes regulating cell proliferation and/or differentiation, but rather behaves as a very mobile protein continuously shuttling between targets located within various cellular compartments (i.e. membrane, microsomes, nucleus...). This allows the receptor to generate both non-genomic and genomic responses. Ligands, growth factors and second messengers produced downstream of activated membrane receptors modulate ER-mediated responses by interfering with the traffic patterns of the receptor, as well as by locally blocking its transient anchorage. Changes in ER turnover rate associated with these regulatory processes seem also to strongly influence the ability of the receptor to mediate gene transactivation. The present paper surveys these biological data and analyzes how they may be integrated into new drug design programs aimed at expanding our therapeutic armamentarium against breast cancer.
Export Options
About this article
Cite this article as:
Leclercq Guy, Lacroix Marc, Laios Ioanna and Laurent Guy, Estrogen Receptor Alpha: Impact of Ligands on Intracellular Shuttling and Turnover Rate in Breast Cancer Cells, Current Cancer Drug Targets 2006; 6 (1) . https://dx.doi.org/10.2174/156800906775471716
DOI https://dx.doi.org/10.2174/156800906775471716 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ovulation, Implantation and Placentation in Females with Obesity and Metabolic Disorders: Life in the Balance
Endocrine, Metabolic & Immune Disorders - Drug Targets Prodrug Design of Phenolic Drugs
Current Pharmaceutical Design Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry Phosphine-Gold(I) Compounds as Anticancer Agents: General Description and Mechanisms of Action
Anti-Cancer Agents in Medicinal Chemistry iNOS: A Potential Therapeutic Target for Malignant Glioma
Current Molecular Medicine Curcumin has Bright Prospects for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Computational Study of the Binding Modes of Diverse DPN Analogues on Estrogen Receptors (ER) and the Biological Evaluation of a New Potential Antiestrogenic Ligand
Anti-Cancer Agents in Medicinal Chemistry ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials 1,3,4-oxadiazole-2-thione Derivatives; Novel Approach for Anticancer and Tubulin Polymerization Inhibitory Activities
Anti-Cancer Agents in Medicinal Chemistry Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets Protein-inorganic Nanohybrids: A Potential Symbiosis in Tissue Engineering
Current Drug Targets The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor
Current Clinical Pharmacology Nanomedicine: A Promising Avenue for the Development of Effective Therapy for Breast Cancer
Current Cancer Drug Targets Potent New Weapons in the Oncology Arsenal (Antibody-Drug Conjugates) Require Unique Biological Manufacturing Expertise
Current Organic Chemistry ZD6474, a Small Molecule Tyrosine Kinase Inhibitor, Potentiates the Anti-Tumor and Anti-Metastasis Effects of Radiation for Human Nasopharyngeal Carcinoma
Current Cancer Drug Targets In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer
Current Drug Research Reviews Mango Polyphenols and Its Protective Effects on Diseases Associated to Oxidative Stress
Current Pharmaceutical Biotechnology Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry